Table 3

Characteristics of hepatitis C virus (HCV) cohort

Number of patients (total)1404
Age at the beginning of follow-up: median (range)47 (16–87)
Gender (%)
 Male604 (43.0)
 Female281 (20.0)
 Unknown519 (37.0)
Ethnicity (%)
 White359 (25.6)
 Mixed11 (0.8)
 Asian53 (3.8)
 Black41 (2.9)
 Other49 (3.5)
 Unknown891 (63.4)
HCV genotype
 1a (%)351 (25.0)
 1b (%)144 (10.3)
 1 other (%)48 (3.4)
 2 (%)58 (4.1)
 3a (%)225 (16.0)
 3 other (%)50 (3.6)
 4 (%)69 (4.9)
 5 (%)2 (0.1)
 6 (%)3 (0.2)
 Unknown (%)454 (32.3)
HBV coinfection
 Yes (%)75 (5.4)
 No (%)1097 (78.1)
 Unknown (%)232 (16.5)
HIV coinfection
 Yes (%)60 (4.3)
 No (%)1077 (76.7)
 Unknown (%)267 (19.0)
Documented comorbidities
 Diabetes (%)111 (7.9)
 Depression (%)253 (18.0)
 Chronic kidney disease (%)18 (1.3)
 Coagulation disorder (%)47 (3.3)
 Cryoglobulinaemia (%)7 (0.5)
 Cancer (%)77 (5.4)
 Liver cancer (%)16 (1.1)
 Other cancer (%)61 (4.3)
Severity of liver disease
 Cirrhosis (%)408 (29.1)
 Decompensated (%)121 (8.6)
 Child–Pugh Score: median (IQR)6.0 (2.0)
 Fibroscan stiffness: median (IQR)8.4 (11.6)
 MELD Score: median (IQR)9.0 (4.7)
Patients treated (%)*914 (65.1)
  • For a continuous variable, median and the IQR are calculated, for a categorical variable, the number and the percentage of patients is provided.

  • *Patients who had at least one episode of treatment recorded.

  • MELD, Model For End-Stage Liver Disease.